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Abstract
Allergen-specific immunotherapy is a potentially disease-modifying therapy that is effective for the treatment of
allergic rhinitis/conjunctivitis, allergic asthma and stinging insect hypersensitivity. However, despite its proven
efficacy in these conditions, it is frequently underutilized in Canada. The decision to proceed with allergen-specific
immunotherapy should be made on a case-by-case basis, taking into account individual patient factors such as the
degree to which symptoms can be reduced by avoidance measures and pharmacological therapy, the amount and
type of medication required to control symptoms, the adverse effects of pharmacological treatment, and patient
preferences. Since this form of therapy carries the risk of anaphylactic reactions, it should only be prescribed by
physicians who are adequately trained in the treatment of allergy. Furthermore, injections must be given under
medical supervision in clinics that are equipped to manage anaphylaxis. In this article, the authors review the
indications and contraindications, patient selection criteria, and the administration, safety and efficacy of allergen-
specific immunotherapy.
Introduction
Allergen-specific immunotherapy (also known as allergy
shots) is an effective treatment used by allergists and
immunologists for common allergic conditions, particu-
larly allergic rhinitis/conjunctivitis, allergic asthma and
stinging insect hypersensitivity [1-4]. This form of ther-
apy typically involves the subcutaneous administration
of gradually increasing quantities of the patient’s rele-
vant allergens until a dose is reached that is effective in
inducing immunologic tolerance to the allergens. The
primary objectives of allergen-specific immunotherapy
are to decrease the symptoms triggered by allergens and
to prevent recurrence of the disease in the long-term.
Currently, it is the only identified disease-modifying
intervention for allergic disease [5,6].
Despite the proven efficacy of immunotherapy for the
treatment of allergic conditions, it is frequently underu-
tilized in Canada [6]. This article will review the
mechanisms of immunotherapy, its indications and con-
traindications, patient selection criteria, and the admin-
istration, safety and efficacy of this form of therapy.
Mechanisms of immunotherapy
Immunologic changes that occur during allergen-specific
immunotherapy are complex and not completely
understood. However, successful immunotherapy has
been associated with a shift from T helper cell type-2
(Th2) immune responses, which are associated with the
development of atopic conditions, to Th1 immune
responses. It is also associated with the production of T
regulatory cells that produce the anti-inflammatory cyto-
kine, interleukin 10 (IL-10), amongst others such as
transforming growth factor (TGF)-beta. IL-10 has been
shown to reduce levels of allergen-specific immunoglo-
bulin E (IgE) antibodies, increase levels of immunoglo-
bulin G (IgG) (blocking) antibodies that play a role in
secondary immune responses, and reduce the release of
pro-inflammatory cytokines from mast cells, eosinophils
and T cells. Allergen-specific immunotherapy has also
been found to decrease the recruitment of mast cells,
basophils, and eosinophils to the skin, nose, eye, and
bronchial mucosa after exposure to allergens, and
reduce the release of mediators, such as histamine, from
basophils and mast cells [5,7]. Research surrounding the
mechanisms of immunotherapy is still ongoing and will
help further elucidate how this form of therapy exerts
its beneficial effects in allergic diseases.
Indications
Allergen-specific immunotherapy is indicated in patients
with allergic rhinitis/conjunctivitis and/or allergic
asthma who have evidence of specific IgE antibodies to
clinically relevant allergens (see Table 1). Skin prick
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cific IgE antibodies. Allergen-specific IgE testing which
provides an in vitro measure of a patient’ss p e c i f i cI g E
levels against particular allergens is a reasonable alterna-
tive to SPT. However, SPTs are generally considered to
be more sensitive and cost effective than allergen-speci-
fic IgE tests [5-7]. Patients with allergic rhinitis/conjunc-
tivitis or allergic asthma who may be good candidates
for immunotherapy include those who: have symptoms
that are not well controlled by pharmacological therapy
or avoidance measures; require high doses of medica-
tion, multiple medications, or both to maintain control
of their disease; experience adverse effects of medica-
tions; or wish to avoid the long-term use of pharmaco-
logical therapy [7].
Venom immunotherapy is indicated in individuals of
all ages with severe systemic reactions to stinging
insects, as well as in adults who experience generalized
reactions that are limited to the skin (see Table 1) [6].
Severe systemic reactions to Hymenoptera (classification
of insects that includes bees and wasps) venom are rela-
tively uncommon, but can be fatal. The purpose of
venom immunotherapy is to reduce the severity of the
reactions and the risk of fatality, and to improve patient
quality of life by allowing the patient to work or play
outdoors without being concerned about the possibility
of experiencing a serious allergic reaction [5].
Contraindications
Allergen-specific immunotherapy is contraindicated in
patients with medical conditions that increase the
patient’s risk of dying from treatment-related systemic
reactions, such as those with severe or poorly controlled
asthma or significant cardiovascular diseases (e.g.,
unstable angina, recent myocardial infarction, significant
arrhythmia, and uncontrolled hypertension) (see Table
1). Immunotherapy is also contraindicated in patients
using beta-blockers since these agents can amplify the
severity of the reaction and make the treatment of sys-
temic reactions more difficult. Immunotherapy should
be considered, however, in patients with life-threatening
stinging insect hypersensitivity, even if they also require
beta-blocker medications, because the fatal risk asso-
ciated with an insect sting is greater than the risk of an
immunotherapy-related systemic reaction [6,7].
Special considerations
Special consideration should be given to the use of aller-
gen-specific immunotherapy in children under 6 years of
age, pregnant women, the elderly, and patients with
malignancy, or immunodeficiency/autoimmune diseases
(see Table 1). Immunotherapy is effective in children
and is often well tolerated. However, children less than
6 years of age may have difficulty cooperating with the
immunotherapy regimen and injections and, therefore,
physicians need to weigh the risks and benefits of ther-
apy in this patient population. Immunotherapy is gener-
ally not initiated in pregnant women; however, it can be
safely continued in women who have been on treatment
prior to becoming pregnant. Special consideration must
also be given to the use of immunotherapy in the elderly
since these patients often have comorbid medical condi-
tions that may increase the risk of experiencing immu-
notherapy-associated adverse events. Finally, some
physicians feel uncomfortable about manipulating the
immune system in patients with autoimmune disorders,
immunodeficiency syndromes, or malignant disease.
However, there is no solid evidence that allergen-specific
immunotherapy is actually harmful to these patients,
provided the risks and benefits of therapy in these
patients have been considered [5].
Efficacy
Venom immunotherapy
Venom immunotherapy provides rapid protection
against Hymenoptera stings. There is a residual risk of
systemic reactions of approximately 5-10% after comple-
tion of venom immunotherapy; however, when reactions
to stings do occur following therapy, they are typically
mild [5]. Clinical features such as a notable history of
Table 1 Allergen-specific Immunotherapy: indications, contraindications and special considerations [5-7]
Indications: • Patients with stinging insect (venom) hypersensitivity
• Patients with allergic rhinitis/conjunctivitis and/or allergic asthma who have evidence of specific IgE antibodies to clinically
relevant allergens; includes patients who:
– Do not achieve control of symptoms with avoidance measures and pharmacotherapy
– Do not want ongoing or long-term pharmacotherapy
– Experience undesirable side effects with pharmacotherapy
Contraindications: • Patients on beta-blockers (relative contraindication with venoms)
• Patients with uncontrolled or severe asthma
• Significant co-morbid diseases such as cardiovascular disability
Special
considerations:
• Children < 6 years of age
• Pregnancy
• The elderly
• Patients with malignancy, immunodeficiency and autoimmune diseases
IgE: immunoglobulin E
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ing immunotherapy, and treatment duration of less than
5 years have been associated with a greater likelihood of
relapse following the discontinuation of venom immu-
notherapy [7].
Allergic rhinitis
Allergen immunotherapy is an effective treatment for aller-
gic rhinitis, particularly for patients with intermittent (sea-
sonal) allergic rhinitis caused by pollens [5,8] It has also
been shown to be effective for the treatment of allergic rhi-
n i t i sc a u s e db yt r e ep o l l e n ,g r ass pollen and ragweed pollen,
house dust mites, cat and dog dander, alternaria, and cock-
roach. Often patient’s symptoms improve even when they
were resistant to conventional drug therapy [5,9].
Evidence suggests that at least 3 years of allergen-spe-
cific immunotherapy provides beneficial effects in
patients with allergic rhinitis that can persist for several
years after discontinuation of therapy [10,11]. In Canada,
most allergists consider stopping immunotherapy after 5
years of adequate treatment. Immunotherapy may also
reduce the risk for the future development of asthma in
patients with allergic rhinitis [5].
Asthma
Immunotherapy has been shown to be effective against
allergic asthma caused by grass, ragweed, house dust
mites, cat and alternaria [6,12]. A Cochrane review of 75
randomized controlled trials examining the use of aller-
gen-specific immunotherapy in asthma management con-
firmed its efficacy in reducing asthma symptom scores and
medication requirements, and improving airway hyperre-
sponsiveness [1]. Similar benefits have been noted with
sublingual immunotherapy [13], which is expected to be
approved in Canada in the near future. Evidence also sug-
gests that allergen-specific immunotherapy may prevent
the onset of asthma in atopic individuals [14,15]. One
study in children with grass and/or birch pollen allergy
found that only 26% of subjects treated with immunother-
apy developed asthma 3 years after completion of treat-
ment compared to 45% who were not treated with
immunotherapy [15]. Allergen-specific immunotherapy
may also modify the progression of established asthma in
children. A study published in the 1960s found that 70%
of treated children no longer had asthma 4 years after
completing immunotherapy compared to 19% of untreated
control subjects, and these results were sustained up to 16
years of age [16]. However, there is no current evidence
that immunotherapy influences the evolution of estab-
lished asthma in adults.
Patient selection
The decision to proceed with allergen-specific immu-
notherapy should be made on a case-by-case basis,
taking into account individual patient factors such as
the degree to which symptoms can be reduced by avoid-
ance measures and pharmacological therapy, the amount
and type of medication required to control symptoms,
and the adverse effects of pharmacological treatment [7].
Furthermore, patients selected for immunotherapy
should be cooperative and compliant. Patients who have
a history of noncompliance or who are mentally or phy-
sically unable to communicate clearly with the treating
physician may be poor candidates for immunotherapy.
Inability to communicate clearly with the physician will
make it difficult for the patient to report signs and
symptoms suggestive of systemic reactions [7].
Venom hypersensitivity
Before deciding to proceed with venom immunotherapy,
it is important to consider the natural history of venom
allergy. Patients who have experienced systemic symp-
toms after a sting are at much greater risk of severe sys-
temic reactions on subsequent stings compared with
patients who have had only local reactions. The fre-
quency of systemic reactions to stings ranges between
5-10% in those who have a history of large local reac-
tions compared to 30-70% in those who have had a pre-
vious systemic reaction. In general, children are at lower
risk of repeated systemic reactions, as are those with a
history of milder reactions [5].
It is also important to consider occupational and geo-
graphic factors that may increase the likelihood of future
stings. For example, bee stings are much more common
in beekeepers, their families, and their neighbors. Yel-
low-jacket stings are more common in certain occupa-
tions such as bakers, grocers and outdoor workers [5].
Allergic rhinitis
Patients with allergic rhinitis who are unable to sleep
because of symptoms or whose symptoms interfere with
their work or school performance are particularly good
candidates for immunotherapy. Those that experience
adverse side effects from pharmacological therapy, such
as nosebleeds from intranasal steroids or excessive
drowsiness from antihistamines, and those who find
pharmacotherapy inconvenient or ineffective, may also
be appropriate candidates for immunotherapy [5]. A
flow diagram for the management of allergic rhinitis is
provided in Figure 1 (for more information on the man-
agement of allergic rhinitis, please see the Allergic Rhi-
nitis article in this supplement).
Asthma
As with allergic rhinitis and venom allergy, the use of
allergen-specific immunotherapy in asthma should be
considered on a case-by-case basis. It can be used prior
to a trial of inhaled corticosteroid (ICS) therapy in
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allergic rhinitis and as add-on therapy in patients using
ICSs alone [12]. Allergen-specific immunotherapy may
also be considered in patients using combination inha-
lers, ICS/leukotriene receptor antagonists (LTRAs) and/
or omalizumab if asthma symptoms are controlled. (see
Figure 2; for more information on the management of
asthma, please see the Asthma article in this supple-
ment). However, to reduce the risk of serious reactions,
asthma symptoms must be controlled and the forced
expiratory volume in 1 second (FEV1)s h o u l db eg r e a t e r
than 70% predicted at the time immunotherapy is
administered.
Immunotherapy administration and schedules
Allergen-specific immunotherapy carries the risk of ana-
phylactic reactions (serious allergic reactions that are
rapid in onset and may cause death) and, therefore,
should only be prescribed by physicians who are ade-
quately trained in the treatment of allergy and the use
of immunotherapy (such as allergists and immunolo-
gists). The injections must be given where a physician is
present, and in clinics that are equipped to manage pos-
sible life-threatening reactions.
Before immunotherapy is started, patients should
understand its benefits, risks, and costs. Counseling
should also include the expected onset of efficacy and
duration of treatment, as well as the risk of anaphylaxis
and importance of adhering to the immunotherapy
schedule. An assessment of the patient’sc u r r e n th e a l t h
status should be made before the administration of
immunotherapy injections to determine whether there
have been any recent changes in the patient’sh e a l t h
that may require modifying or withholding treatment (e.
g., uncontrolled/symptomatic asthma or exacerbation of
allergy symptoms) [7].
Once it has been determined that the patient is suita-
ble for immunotherapy, the allergist/immunologist will
use extracts of clinically relevant allergens for immu-
notherapy treatment sets. Allergen extracts are commer-
cially available for most of the commonly recognized
allergens (e.g., grass and tree pollen, house dust mites,
insect venom). When possible, standardized extracts
should be utilized to prepare treatment sets since the
efficacy and safety of immunotherapy are dependent on
the quality of the allergen extracts used. In choosing the
components for a clinically relevant allergen immu-
notherapy extract, the physician must also be familiar
with local and regional aerobiology and indoor and out-
door allergens, paying special attention to potential
allergens in the patient’s own environment. Table 2 pro-
vides the timing and concentration of common pollen
a n dm o u l da l l e r g e n sa c r o s st h ev a r i o u sg e o g r a p h i c
regions in Canada [6,7].
Typically, allergen-specific immunotherapy consists of
two phases: a build-up phase (also known as up-dosing
or induction) and a maintenance phase. During the
build-up phase, the patient receives weekly injections,
starting with a very low dose, with gradual increases in
dose over the course of 5-8 months. After this period,
the patient has usually built up sufficient tolerance to
the allergen such that a maintenance (therapeutic) dose
has been reached. During the maintenance phase, the
patient receives injections of the maintenance dose
every 3 to 4 weeks, usually for a period of 3 to 5 years.
After this period, many patients experience a prolonged,
protective effect and, therefore, consideration can be
given to stopping therapy [7].
Accelerated schedules, such as rush or cluster immu-
notherapy, may also be used and involve the administra-
tion of several injections at increasing doses on a single
visit. With cluster immunotherapy, two or three injec-
tions (at increasing doses) are given sequentially in a
single day of treatment on non-consecutive days. Rush
immunotherapy entails administering incremental doses
of the allergen at intervals varying between 15 and 60
minutes over 1 to 3 days until the target maintenance
dose is achieved. Although accelerated schedules offer
the advantage of achieving the therapeutic dose much
earlier than conventional immunotherapy schedules,
Leukotriene receptor 
antagonists
Allergen immunotherapy
Intranasal corticosteroids
Allergen avoidance
Oral antihistamines
Figure 1 A simplified, stepwise algorithm for the treatment of
allergic rhinitis. Note: Treatments can be used individually or
in any combination.
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systemic reactions, and are not typically used in Canada
for respiratory allergies [5,7].
Pre-seasonal immunotherapy preparations that are
administered on an annual basis are also available. They
offer a much shorter build-up phase. Sublingual pre-
parations are also expected to be approved in Canada in
the near future. These should provide patients with
effective therapeutic options. Although patients will be
able to self-administer the sublingual formulations, close
monitoring by a physician will still be required.
Patients receiving maintenance immunotherapy should
be followed regularly to: assess the efficacy of treatment;
monitor adverse reactions; assess patient compliance
with therapy; and determine whether immunotherapy
can be discontinued or if dose/schedule adjustments are
required. For example, dose reductions may need to be
considered during periods when the patient is exposed
to increased allergen levels or when he/she is experien-
cing an exacerbation of symptoms.
At present, there are no specific tests or clinical mar-
kers that will distinguish between patients who will
relapse and those who will remain in long-term clinical
remission after discontinuing allergen immunotherapy.
Therefore, the decision to continue immunotherapy
beyond 3 to 5 years should be based on individual
patient factors such at the severity of the disease, bene-
fits sustained from treatment, reaction history, patient
preference, and treatment convenience [7].
Safety
Allergen-specific immunotherapy is generally safe and
well-tolerated when used in appropriately selected
patients. However, local and systemic reactions may
occur. Local reactions, such as redness or itching at the
injection site, can generally be managed with local treat-
ment (e.g., cool compresses or topical corticosteroids) or
oral antihistamines. Systemic reactions occur in approxi-
mately 1-4% of patients on allergen immunotherapy [6]
and can be mild to severe. The most severe reaction is
anaphylaxis. Fatal anaphylactic reactions are rare, occur-
ring in an estimated 1 in every 8 million doses of immu-
notherapy administered [6].
There are numerous signs and symptoms of anaphy-
laxis that involve the skin, gastrointestinal and respira-
tory tracts, and cardiovascular system (see Table 3) [17].
These symptoms typically develop within 30 minutes
after the immunotherapy injection. In fact, most docu-
mented fatalities (73%) have occurred within 30 minutes
of the injection [6]. It is important to note that the signs
and symptoms of anaphylaxis are unpredictable and may
vary from patient to patient. Therefore, the absence of
Combination ICS/LABA 
or ICS/LTRA
Allergen-specific 
immunotherapy
Inhaled corticosteroids (ICS) or LTRA
Anti-IgE or oral prednisone
Avoidance measures
Rapid-acting beta2-agonist 
as needed
Figure 2 A simplified, stepwise algorithm for the treatment of asthma. ICS: inhaled corticosteroid; LTRA: leukotriene receptor antagonist; LABA:
long-acting beta2-agonist; IgE: immunoglobulin E Note: Treatments can be used individually or in any combination.
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does not rule out anaphylaxis, and should not delay
immediate treatment [6].
In the event of anaphylaxis, the treatment of choice is
epinephrine administered by intramuscular injection
into the lateral thigh (see Anaphylaxis article in this
supplement for more information on the diagnosis and
management of anaphylaxis). Adjunctive therapies such
as antihistamines, bronchodilators and systemic corti-
costeroids may also be used, but should never be given
prior to or replace epinephrine in the treatment of ana-
phylaxis. In severe cases, intravenous saline or supple-
mental oxygen may be required [5-7].
Following a systemic reaction to immunotherapy, con-
sideration should be given to reducing the therapeutic
dose or to possibly discontinuing therapy, particularly if
the patient has repeated systemic reactions following
injections [5-7].
Conclusions
Allergen-specific immunotherapy is a potentially dis-
ease-modifying therapy that is effective for the treatment
of allergic rhinitis/conjunctivitis, allergic asthma and
stinging insect hypersensitivity. Although it is still
unclear exactly how this form of therapy works, immu-
notherapy has been associated with a shift from Th2 to
Th1 immune responses, and the production of T regula-
tory cells that dampen the immune response to relevant
allergens. When used in appropriately-selected patients,
allergen-specific immunotherapy is extremely safe. This
form of therapy, however, does carry the risk of anaphy-
lactic reactions and, therefore, should only be prescribed
by physicians who are adequately trained in the treat-
ment of allergy. Furthermore, immunotherapy should be
administered only by physicians who are equipped to
manage life-threatening anaphylaxis.
Key take-home messages
￿ Allergen-specific immunotherapy is a potentially dis-
ease-modifying therapy that is effective for the treatment
of allergic rhinitis/conjunctivitis, allergic asthma and
stinging insect hypersensitivity.
￿ Allergen immunotherapy is contraindicated in
patients on beta-blockers, those with uncontrolled or
severe asthma, or those with significant co-morbid car-
diovascular disease.
￿ The decision to proceed with allergen immunother-
apy should be made on a case-by-case basis, taking into
Table 2 Timing and concentration of suspect pollens and mould spores in various geographic areas across Canada [6]
Tree pollen Grass pollen Weed pollen Mould spores
British
Columbia
(Coastal)
• Season: early February to mid-July
• Primarily deciduous trees (alder, birch,
poplar, elm, oak)
• Season: end of April to
September
• Highest grass concentrations:
early June to mid-July
• Not usually a major
factor; no native
ragweed
• Levels higher in the spring;
increase further in September
and October
• Most prevalent spores:
Cladosporium and
basidiomycetes
British
Columbia
(Interior)
• Season: late March to mid-July
• Primarily deciduous trees (willow,
birch, poplar)
• Season starts in early May in
southern parts of the province;
starts up to 1 month later in
northern parts
• Ragweed is minimal • Cladosporium can occur from
April to late fall
Prairies • Season starts in the first week of April
and continues through June&#8226
Main deciduous trees: birch and poplar;
alder, maple, elm, oak, ash, and willow
may also contribute
• Season starts in mid‐May and
continues to the end of
September&#8226 Peak season
is usually mid‐June to early July
• Most common weeds:
nettles or sage
brush&#8226 Some
ragweed, especially in
Manitoba)
• Can occur through the spring,
summer, and early fall&#8226
Alternaria and Cladosporium are
the predominant moulds
Ontario
and
Quebec
• Season starts early April in southern
Ontario and Quebec; may occur 6
weeks later in northern areas
• In southern Ontario, most common
are deciduous trees (birch, poplar, oak,
maple, ash, elm, mulberry, willow,
chestnut, hickory)
• In northern Ontario, birch and poplar
most common
• In Quebec, ash, poplar, birch most
common; maple, alder and oak are less
prevalent
• Season starts mid-to-late May;
a couple of weeks later in
northern areas
• Latter part of May and mid-
June are peak seasons for grass
pollination
• Ragweed season in
Southern Ontario and
Southwestern Quebec
begins early-to-mid
August
• Reaches peak in late
August/early September
• Stops at first frost
• Nettle and plantain can
also contribute
• Occur during spring, summer
and fall months
• Concentrations may be higher
late summer to fall months in
Quebec
• Alternaria and Cladosporium
are the predominant moulds
Maritimes • Season in New Brunswick and Nova
Scotia: late March to last week of June
• Primarily deciduous trees (birch,
poplar, alder, maple, oak, and ash)
• Season: mid-May to end of
September
• Peaks in early June
• Ragweed: early August
to end of September
• Levels higher during the late
summer and early fall months
• Alternaria and Cladosporium
are the predominant moulds
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ity, efficacy of avoidance measures and pharmacological
therapy, and patient preferences.
￿ Allergen immunotherapy carries the risk of anaphy-
lactic reactions and, therefore, should only be prescribed
by physicians who are adequately trained in the treat-
ment of allergy
￿ Injections must be given under medical supervision
in clinics that are equipped to manage life-threatening
anaphylaxis.
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Table 3 Signs and symptoms of anaphylaxis [17]
Signs/symptoms Incidence
Urticaria, angioedema 87%
Dyspnea 59%
Dizziness, syncope 33%
Diarrhea, abdominal cramps 29%
Flushing 25%
Upper airway edema 21%
Nausea, vomiting 20%
Hypotension 15%
Rhinitis 8%
Itch without rash 5%
Seizure 1%
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